Literature DB >> 19273669

Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.

Michael L Beeton1, Victoria J Chalker, Nicola C Maxwell, Sailesh Kotecha, O Brad Spiller.   

Abstract

Antibiotic resistance determination of Ureaplasma spp. (Ureaplasma parvum and Ureaplasma urealyticum) usually requires predetermination of bacterial titer, followed by antibiotic interrogation using a set bacterial input. This 96-well method allows simultaneous quantification of bacteria in the presence and absence of antibiotics. A method for determining precise MICs and a method for screening against multiple antibiotics using breakpoint thresholds are detailed. Of the 61 Ureaplasma-positive clinical isolates screened, one (1.6%) was resistant to erythromycin (MIC, >64 mg/liter) and clarithromycin (MIC, 4 mg/liter), one to ciprofloxacin (1.6%), and one to tetracycline/doxycycline (1.6%). Five isolates were also consistently found to have an elevated MIC of 8 mg/liter for erythromycin, but this may not represent true antibiotic resistance, as no mutations were found in the 23S rRNA operons or ribosome-associated L4 and L22 proteins for these strains. However, two amino acids (R66Q67) were deleted from the L4 protein of the erythromycin-/clarithromycin-resistant strain. The tetM genetic element was detected in the tetracycline-resistant clinical isolate as well as in the positive control Vancouver strain serotype 9. The tetM gene was also found in a fully tetracycline-susceptible Ureaplasma clinical isolate, and no mutations were found in the coding region that would explain its failure to mediate tetracycline resistance. An amino acid substitution (D82N) was found in the ParC subunit of the ciprofloxacin-resistant isolate, adjacent to the S83L mutation reported by other investigators in many ciprofloxacin-resistant Ureaplasma isolates. It is now possible to detect antibiotic resistance in Ureaplasma within 48 h of positive culture without prior knowledge of bacterial load, identifying them for further molecular analysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273669      PMCID: PMC2681543          DOI: 10.1128/AAC.01349-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones.

Authors:  C M Bébéar; H Renaudin; A Charron; M Clerc; S Pereyre; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  Characterization of tetracycline-resistant strains of Ureaplasma urealyticum.

Authors:  J A Robertson; G W Stemke; S G Maclellan; D E Taylor
Journal:  J Antimicrob Chemother       Date:  1988-03       Impact factor: 5.790

3.  The nucleotide sequence of the tetracycline resistance determinant tetM from Ureaplasma urealyticum.

Authors:  R Sanchez-Pescador; J T Brown; M Roberts; M S Urdea
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum.

Authors:  M C Roberts; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

5.  Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.

Authors:  A Tait-Kamradt; T Davies; P C Appelbaum; F Depardieu; P Courvalin; J Petitpas; L Wondrack; A Walker; M R Jacobs; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates.

Authors:  K B Waites; D T Crouse; G H Cassell
Journal:  Pediatr Infect Dis J       Date:  1992-01       Impact factor: 2.129

8.  TetM tetracycline-resistant determinants in Ureaplasma urealyticum.

Authors:  M C Roberts; G E Kenny
Journal:  Pediatr Infect Dis       Date:  1986 Nov-Dec

9.  Study of isolation of fluoroquinolone-resistant Ureaplasma urealyticum and identification of mutant sites.

Authors:  Wenbo Zhang; Yimou Wu; Weiguo Yin; Minjun Yu
Journal:  Chin Med J (Engl)       Date:  2002-10       Impact factor: 2.628

10.  Mechanisms of macrolide resistance in Ureaplasma urealyticum: a study on collection and clinical strains.

Authors:  G Palù; S Valisena; M F Barile; G A Meloni
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

View more
  21 in total

1.  In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan.

Authors:  Yasuhiro Kawai; Yukiko Nakura; Tetsu Wakimoto; Makoto Nomiyama; Tsugumichi Tokuda; Toshimitsu Takayanagi; Jun Shiraishi; Kenshi Wasada; Hiroyuki Kitajima; Tomio Fujita; Masahiro Nakayama; Nobuaki Mitsuda; Isao Nakanishi; Makoto Takeuchi; Itaru Yanagihara
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Chromosomal mutations responsible for fluoroquinolone resistance in Ureaplasma species in the United States.

Authors:  Li Xiao; Donna M Crabb; Lynn B Duffy; Vanya Paralanov; John I Glass; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

3.  Antimicrobial Susceptibility and Clonality of Clinical Ureaplasma Isolates in the United States.

Authors:  Javier Fernández; Melissa J Karau; Scott A Cunningham; Kerryl E Greenwood-Quaintance; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis.

Authors:  E Amram; I Mikula; C Schnee; R D Ayling; R A J Nicholas; R S Rosales; S Harrus; I Lysnyansky
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

5.  Random insertion and gene disruption via transposon mutagenesis of Ureaplasma parvum using a mini-transposon plasmid.

Authors:  Ali F Aboklaish; Emilie Dordet-Frisoni; Christine Citti; Mark A Toleman; John I Glass; O Brad Spiller
Journal:  Int J Med Microbiol       Date:  2014-09-26       Impact factor: 3.473

6.  Antibiotic Susceptibility and Sequence Type Distribution of Ureaplasma Species Isolated from Genital Samples in Switzerland.

Authors:  Sarah C Schneider; Regula Tinguely; Sara Droz; Markus Hilty; Valentina Donà; Thomas Bodmer; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

7.  Antimicrobial resistance in clinical isolates of Ureaplasma spp. from samples in Germany.

Authors:  Roger Dumke
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

8.  Incidence and antibiotic susceptibility of genital mycoplasmas in sexually active individuals in Hungary.

Authors:  K Pónyai; N Mihalik; E Ostorházi; B Farkas; L Párducz; M Marschalkó; S Kárpáti; F Rozgonyi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-18       Impact factor: 3.267

9.  Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum in asymptomatic women in Northern Greece.

Authors:  Tz Kotrotsiou; M Exindari; E Diza; G Gioula; A Melidou; K Kaplanis; N Malisiovas
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

10.  Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from Neonates in England and Wales between 2007 and 2013.

Authors:  Michael L Beeton; Victoria J Chalker; Lucy C Jones; Nicola C Maxwell; O Brad Spiller
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.